Connect Biopharma Holdings Limited (CNTB)

CNTB Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Dec 31, 2020
Revenue	26.03	-	-	-	-
Gross Profit	26.03	-	-	-	-
Selling, General & Admin	19.23	16.05	20.81	19.01	7.31
Research & Development	29.26	53	96.63	80.5	23.12
Other Operating Expenses	-	-	-1.08	-1.85	-1.07
Operating Expenses	48.49	69.06	116.36	97.66	29.36
Operating Income	-22.45	-69.06	-116.36	-97.66	-29.36
Interest Expense	-	-	-0.02	-0.01	-0.44
Interest & Investment Income	4.45	5.22	1.81	0.17	0.21
Currency Exchange Gain (Loss)	-	-	1.47	-0.52	-1.04
Other Non Operating Income (Expenses)	2.59	1.85	-	-103.98	-88.73
EBT Excluding Unusual Items	-15.41	-61.99	-113.1	-202	-119.36
Asset Writedown	-	-	-4.7	-	-
Pretax Income	-15.41	-61.99	-117.79	-202	-119.36
Income Tax Expense	0.22	0.12	0.3	0.27	-
Earnings From Continuing Operations	-15.63	-62.11	-118.09	-202.27	-119.36
Net Income	-15.63	-62.11	-118.09	-202.27	-119.36
Net Income to Common	-15.63	-62.11	-118.09	-202.27	-119.36
Shares Outstanding (Basic)	55	55	55	52	17
Shares Outstanding (Diluted)	55	55	55	52	17
Shares Change (YoY)	0.27%	0.04%	5.50%	205.31%	1.27%
EPS (Basic)	-0.28	-1.13	-2.15	-3.88	-6.98
EPS (Diluted)	-0.28	-1.13	-2.15	-3.88	-6.98
Free Cash Flow	-24.36	-47.82	-105.93	-88.16	-27.9
Free Cash Flow Per Share	-0.44	-0.87	-1.92	-1.69	-1.63
Gross Margin	100.00%	-	-	-	-
Operating Margin	-86.24%	-	-	-	-
Profit Margin	-60.03%	-	-	-	-
Free Cash Flow Margin	-93.58%	-	-	-	-
EBITDA	-21.79	-68.34	-115.63	-97.17	-29.21
EBITDA Margin	-83.71%	-	-	-	-
D&A For EBITDA	0.66	0.72	0.73	0.49	0.15
EBIT	-22.45	-69.06	-116.36	-97.66	-29.36
EBIT Margin	-86.24%	-	-	-	-
Revenue as Reported	26.03	-	-	-	-

Updated Sep 5, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q